Go Pro
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel
LON:GSK

GSK Interim Earnings Report

GSK logo
GBX 1,961 +41.50 (+2.16%)
As of 07/27/2026 12:11 PM Eastern
ProfileEarnings HistoryForecast

GSK EPS Results

Actual EPS
GBX 75.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GSK Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GSK Announcement Details

Quarter
Interim
Date
7/30/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

GSK Earnings Headlines

GSK Adds 70,759 Shares to LSE Listing Under 2022 Share Save Plan
July 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/gsk-adds-70759-shares-to-lse-listing-under-2022-share-save-plan?utm_source=marketbeat.com&utm_medium=referral
GSK enters lung cancer market with FDA nod for Jideytro
July 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4616830-gsk-wins-fda-nod-jideytro-lung-cancer-drug
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.tc pixel
 |  Porter & Company (Ad)
GSK Gets U.S. Approval for Jideytro for Certain Lung Cancers
July 22, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/gsk-gets-u-s-approval-for-jideytro-for-certain-lung-cancers-cde7fb67
GSK lung cancer drug gets speedy approval following $10.6B deal
July 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-lung-cancer-drug-gets-163000133.html
GSK enters lung cancer drug market with early FDA nod for Jideytro
July 22, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/gsk-enters-lung-cancer-drug-market-with-early-fda-nod-for-jideytro/ar-AA28tkyz
See More GSK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GSK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GSK and other key companies, straight to your email.

About GSK

GSK (LON:GSK), together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

View GSK Profile
Earnings Tools